KalVista Pharmaceuticals, Inc. is a high-risk pharmaceutical company in the United States that specializes in developing small molecule protease inhibitors for various diseases. With a risk rating score of 32.5, the company focuses on ESG factors in the discovery, development, and commercialization of its products. Operating throughout the US, KalVista Pharmaceuticals aims to provide small molecule plasma kallikrein inhibitors for hereditary angioedema and diabetic macular edema.